ANTIBIOTIC RESISTANCE PROFILING AND MICROBIOTA OF THE UPPER RESPIRATORY TRACT OF APPARENTLY HEALTHY DOGS IN IBADAN, SOUTH WEST NIGERIA. by Daodu, Oluwafemi Babatunde et al.
Daodu et al., Afr., J. Infect. Dis. (2017) 11 (1): 1-11
http://dx.doi.org/10.21010/ajid.v11i1.1
1
ANTIBIOTIC RESISTANCE PROFILING AND MICROBIOTA OF THE UPPER RESPIRATORY
TRACT OF APPARENTLY HEALTHY DOGS IN IBADAN, SOUTH WEST NIGERIA.
Oluwafemi Babatunde Daodu*, Elizabeth Adesola Amosun2 and Daniel Oladimeji Oluwayelu2
1Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Ilorin, Ilorin,
Nigeria, 2Department of Veterinary Microbiology and Parasitology, Faculty of Veterinary Medicine,
University of Ibadan, Ibadan, Nigeria.
*Corresponding author E-mail: daodu.femi@gmail.com daodu.ob@unilorin.edu.ng, +2348130821559
Abstract
Background: Rearing of dogs and other pets has become increasingly popular in modern society. Bacterial flora resides within the
nasal and oral cavities of dogs and when chanced, can be pathogenic. Certain similarities between humans and dogs portends
dangerous behavioral habits that could lead to zoonotic disease transmission. This study was aimed at isolation, identification and
antibiotic profiling of bacteria from nasal swabs of apparently healthy dogs. The zoonotic risk was also considered.
Methodology: A total of 173 nasal swabs were collected from 173 apparently healthy dogs. Structured questionnaires were
administered to investigate human behavioral habits.
Results: Two hundred and twenty two (222) bacterial isolates were obtained from the culture with ten (10) potentially pathogenic
bacteria in the order of Escherichia coli (18.5%), Proteus species (17.1%), Staphylococcus aureus (14.0%), Klebsiella species
(9.0%), Acinetobacter species (9.0%), coagulase negative Staphylococcus species (7.7%), Pseudomonas species (6.8%),
Actinobacter species (6.8%), Citrobacter species (5.9%) and Streptococcus species (5.4%). Overall, the Gram negative isolates
showed resistance to ciprofloxacin (9.3%), sparfloxacin (16.0%),perfloxacin (17.3%), ofloxacin (21.6%), chloramphenicol (34..6%),
gentamycin (36.4%), streptomycin (37.%), septrin (49.4%), amoxillin (59.3%), augmentin (62.3%) while the Gram positive bacteria
showed resistance to ciprofloxacin (3.3%), perfloxacin (6.7%), erythromycin (13.3%), streptomycin (21.7%), rocephin (28.3%),
septrin (28.3%), gentamycin (36.7%), zinnacef (68.3%), ampiclox (81.7%) and amoxillin (85.0%). Multi-drug resistance (MDR) to
three or more antimicrobials was observed in some of the isolates. Seventy - seven resistance patterns were observed, 16 in Gram
positive and 61 in Gram negative bacteria.
Conclusion: This study revealed MDR to two or more antimicrobials in all the isolates. These can pose antibiotic resistance
challenges in situation of primary or secondary canine respiratory infections. Also, this study revealed that 82% of the dog owners/
lovers had less than 50cm face-to-face contact with these dogs while playing with them, thus increasing their chances of acquiring
MDR bacteria from apparently healthy dogs.
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Introduction
The relationship between people and dogs is unique. Among domesticated hunting of prey animals, dogs are capable of
performing a wide variety of roles for human: sheep herding, sniffing out drugs and explosives, hunting of prey and security;
breeding purposes and companionship (Pet). To be precise about when the friendship began, is very difficult but a reasonable guess
suggest that it has been going strong for more than 14,000 years (Bradshaw 2012; Udell et al., 2008). Despite the fact that we live so
closely with dogs, it is not entirely without any health risk. A high zoonotic risk is involved with the increasing number of people,
rich and poor, keeping dogs for various purposes without much knowledge on the zoonoses (Omudu et al., 2010).
Surveys of microbiota of the nasal cavities, tonsils, and pharynx of clinically healthy dogs have found many types of aerobic and
facultative anaerobic bacteria (Weese, 2007) most of which are zoonotic and may escape into the air while the dog breaths. Greater
numbers of organisms are routinely cultured from the rostral than from the caudal nasal cavity of dogs (Craig, 2011). Craig, 2011
reported that the same bacteria flora may not possibly be found in nasal cavity and pharynx in each animal because of marked
individual variations, but the presence of a certain range of microbiota can be predicted (Craig, 2011). However, the antibiotic
resistance reports of bacteria isolated from clinically healthy animals is continuously increasing (Coates et al., 2002; Davis et al.,
2014; Henning et al., 2001; Manian, 2003). Since these resistance factors are transferable, antibiotic sensitive microbiota of human
may acquire these resistance factors (Lee, 2003) after effective zoonotic transmission including direct contact with pets, contact
with feces from pets, preparation of raw meat and bones for pet consumption, and the handling of commercial pet treats (Cherry et
al., 2004; Health Canada, 2005).
Currently, the behavioral habits of dog owners/lovers may expose them to pathogenic agents through either inhalation,
ingestion, skin contact etc. The aerosolized transmission of disease can occur through both “droplet” and “airborne” means. Droplet
transmission is defined as the transmission of diseases by expelled particles that are likely to settle into another surface quickly,
typically within three feet (90 cm) of the source (Practical Guidelines for Infection Control in Health Care Facilities 2005). Thus, for
example, for an infection to be caused by droplet transmission, a susceptible individual must be close enough to the source of the
infection for the droplet (containing the infectious microorganism) to make contact with the susceptible individual’s respiratory tract,
eyes, mouth, nasal passages, and so forth (Gralton et al., 2011). The increase in antibiotic resistance among many potential
pathogenic bacteria poses a great threat to humans who inhale aerosolised bacteria from the dog’s nostril, mouth, or fur etc.
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This study was carried out to determine the potential pathogenic bacteria in the nasal region of the upper respiratory tract
of apparently healthy dogs, antibiotic resistance patterns of the isolated bacteria and the level of closeness (distance) between the dog
owner/handler's face and the body of the dog.
Materials and Methods
Collection of samples
Nasal samples were collected from the vestibules of 173 dogs by using sterile swabs. These dogs were clinically healthy
and were used as guards, pets, and for breeding and hunting purposes in urban and rural areas of Ibadan, Oyo state, Nigeria. None of
the dogs had apparent bacterial infections or was receiving antimicrobial therapy at the time of sample collection. In an attempt to
sample a representative portion of the population, samples were collected at irregular intervals. Also, close observation and
structured questionnaire administration were done involving the human with closest interaction with the dog sampled. This was done
to determine the actual closest human face to dog body distance when playing with the dog. Only one sample was collected per
animal. Samples collected were transported in a cooler with ice packs for delivery to the Department of Veterinary Microbiology
and Parasitology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria, for bacteriological analysis.
Isolation and identification of bacterial isolates
Each nasal sample was inoculated unto nine milliliters of sterile tryptic soy broth (TSB) (OXOID, Basingstoke, UK) in
universal bottles. The broth cultures were incubated at 37°C for 18 to 24 h. After incubation, a loopful of the TSB culture was
inoculated onto MacConkey agar, 7% sheep blood agar, Eosin Methylene Blue (EMB) (LAB M, lancashire, UK). These inoculated
media were incubated at 37°C for 18 to 24 h. Colonial morphology and Gram staining of all the isolates on the plates were carried
out; all the isolates were selected for oxidase and catalase production. Coagulase test was carried out for all the Gram positive cocci
in clusters. Haemolysis was observed and recorded. Other biochemical and sugar utilization tests were performed. Results of
biochemical tests were interpreted using Cowan and Steel’s manual for the identification of medical bacteria 3rd edition (Barrow et
al., 2003).
Antimicrobial Susceptibility Test
The susceptibility of identified bacterial isolates to antimicrobial agents was determined by the standard Kirby-Bauer disk
diffusion method. Susceptibility to the following antimicrobials was determined for sixty Gram positive bacterial isolates:
amoxicillin (30μg), ampiclox (30μg), ciprofloxacin (10μg), rocephin (25μg), perfloxacin (10μg), zinnacef (30μg), erythromycin 
(10μg), gentamicin (10μg), septrin (30μg), streptomycin (10μg) while One hundred and sixty- five Gram negative bacterial isolates 
were tested for susceptibility to the following antibiotics: augmentin (30μg), ofloxacin (5μg), gentamycin (10μg) and ciprofloxacin 
(5μg), perfloxacin (10μg), streptomycin (10μg), amoxicillin (30μg), chloramphenicol (30μg)), septrin (30μg), sparfloxacin (10μg). 
Results
A total of 222 bacterial isolates were obtained from 173 nasal swabs of apparently healthy dogs. The isolates included
Escherichia coli 41 (18.5%) followed by Proteus species 38 (17.1%), Staphylococcus aureus 31 (14.0%), Klebsiella species 20
(9.0%), Acinetobacter species 20 (9.0%), coagulase negative Staphylococcus species 17 (7.7%), Pseudomonas species 15 (6.8%),
Actinobacter species 15 (6.8%), Citrobacter species 13 (5.9%) and Streptococcus species 12 (5.4%) (Table 1, Chart 1).
Staphylococcus aureus and Escherichia coli ranked highest in the isolation frequency for Gram positive and Gram negative bacteria
respectively (Table 1).
The overall rate of Staphylococcus aureus (n= 31) displayed 26 (84%), 26 (84%), 21 (68%), 11 (35.5%), 8 (25.8%), 7
(22.6%), 5 (16.0%), 5 (16.0%), 2 (6.5%), 0 (0.0%) resistance to Ampiclox, Amoxicillin, Zinnacef, Gentamycin, Septrin,
Streptomycin, Rocephin, Erythromycin, Perfloxacin and Ciprofloxacin respectively. Streptococcus species (n=12) showed 11
(92.0%), 11 (92.0%), 9 (75.0%), 8 (66.7%), 6 (50.0%), 6 (50.0%), 6 (50.0%), 3 (25.0%), 2 (16.7%) and 2 (16.7%) to Ampiclox,
Amoxicillin, Zinnacef, Gentamycin, Rocephin, Septrin, Streptomycin, Erythromycin, Perfloxacin and Ciprofloxacin. Coagulase
negative Staphylococcus species (n=17) had resistance 13 (77.0%), 14 (82.4%), 11 (65.0%), 6 (35.0%), 3 (17.6%), 3 (17.6%), 0
(0.0%), 0 (0.0%), 0 (0.0%) and 0 (0.0%) to Ampiclox, Amoxicillin, Zinnacef, Rocephin, Gentamycin, Septrin, Streptomycin,
Perfloxacin, Ciprofloxacin and Erythromycin respectively (Table 2). Generally, more than 50% of the gram positive isolates (range:
68.3% - 85.0%) were resistance to Ampiclox, Zinnacef and Amoxicillin (Table 3, Chart 2) while one isolate of Staphylococcus
aureus and two isolates of Streptococcus species were resistant to eight out of ten antibiotics used (Table 6).
Escherichia coli (n= 41) displayed 22 (53.7%), 20 (48.8%), 16 (39.0%), 14 (34.1%), 12 (29.3%), 9 (22.0%), 8 (19.5%), 6
(14.6%), 4 (9.8%) and 3 (7.3%) to Amoxacillin, Augmentin, Septrin, Streptomycin, Gentamycin, Chloramphenicol, Ofloxacin,
Sparfloxacin, Perfloxacin and Ciprofloxacin respectively. Proteus species (n=38) had 29 (76.3%), 29 (76.3%), 29 (76.3%), 20
(52.6%), 18 (47.4%), 17 (44.7%), 12 (31.6%), 7 (18.4%), 7 (18.4%) and 6 (15.8%) resistance to Amoxacillin, Augmentin, Septrin,
Chloramphenicol, Streptomycin, Gentamycin, Ofloxacin, Sparfloxacin, Perfloxacin and Ciprofloxacin respectively. Klebsiella
species showed 7 (35.0%), 7 (35.0%), 6 (30.0%), 6 (30.0%), 5 (25.0%), 5 (25.0% ), 5 (25.0% ), 4 (20.0% ), 3 (15.0%) and 1 (5.0% )
resistance to Septrin, Chloramphenicol, Amoxacillin, Augmentin, Gentamycin, Perfloxacin, Ofloxacin, Streptomycin, Sparfloxacin
and Ciprofloxacin respectively. Acinetobacter species (n=20 had resistance 12 (60.0%), 11 (55%), 10 (50%), 9 (45.0%), 9 (45.0%),
7 (35.0%), 4 (20.0% ), 4 (20.0% ), 4 (20.0% ) and 3 (15.0% ) to Amoxacillin, Augmentin, Septrin, Gentamycin, Streptomycin,
Chloramphenicol, Sparfloxacin, Perfloxacin, Ofloxacin and Ciprofloxacin respectively. Pseudomonas species (n=15) showed 14
(93.3%), 9 (60.0%), 8 (53.3%), 8 (53.3% ), 6( 40.0%), 5 (33.3%), 2 (13.3%), 0 (0.0% ), 0 (0.0%) and 0 (0.0%) resistance to
Augmentin, Amoxacillin, Septrin, Gentamycin, Streptomycin, Chloramphenicol, Perfloxacin, Sparfloxacin, Ciprofloxacin and
Ofloxacin respectively. Actinobacter species (n=15) had 10 (66.7%), 9 (60.0%), 5 (33.3%), 5 (33.3%), 4 (26.7%), 4 (26.7%), 3
(20.0%), 3 (20.0%), 3 (20.0%) and 1 (6.7%) resistance to Augmentin, Amoxacillin, Septrin, Streptomycin, Chloramphenicol,
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Gentamycin, Sparfloxacin, Perfloxacin, Ofloxacin and Ciprofloxacin respectively. Citrobacter species (n=13) had resistance 11
(84.6%), 9 (69.2%), 5 (38.5%), 4 (30.8%), 5 (38.5%), 4 (30.8%), 3 (23.1%), 3 (23.1%), 3 (23.1%) and 1 (7.7%) to Augmentin,
Amoxacillin, Septrin, Chloramphenicol, Streptomycin, Gentamycin, Sparfloxacin, Perfloxacin, Ofloxacin and Ciprofloxacin
respectively (Table 4). Generally, more than 50% of the Gram negative isolates (range: 59.3% - 62.3%) were resistance to
Amoxicillin and Augmentin (Table 5, Chart 3). One each of Escherichia coli, Klebsiella species, Pseudomonas species,
Actinobacter species and Citrobacter species isolates, two Acinetobacter species isolates and four Proteus species isolates were
resistance to ten different antibiotics (Table 7).
It was obtained from the questionnaire that 82% (123/150) of human had contacts, at different times, less than 50cm
human face to dog body contact especially when playing with the dogs. 60 (40%) human contacts respondents belong to urban areas
where dogs are majorly used as pet, security and breeding purpose while 63(42%) of human contacts belong to rural areas where
dogs are majorly used for hunting purpose.
Table 1: Distribution of bacteria isolates
Bacteria Frequency (%)
Gram positive isolates 60 (27.0%)
Staphylococcus aureus 31 (14.0%)
Coagulase negative Staphylococcus species 17 (7.7%)
Streptococcus species 12 (5.4%)
Gram negative isolates 162 (73.0%)
Escherichia coli 41 (18.5%)
Proteus species 38 (17.1%)
Klebsiella species 20 (9.0%)
Acinetobacter species 20 (9.0%)
Pseudomonas species 15 (6.8%)
Actinobacter species 15 (6.8%)
Citrobacter species 13 (5.9%)
Total number of isolates 222 (100%)
Chart 1: Percentage distribution of bacteria isolates
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Table 2: Antibiotic resistance patterns for Gram positive isolates
Table 3: Antibiotic resistance patterns for Gram positive isolates
Test drugs Amount (µg) Sensitive Resistant
Ciprofloxacin 10 58(96.7%) 2(3.3%)
Perfloxacin 10 56(93.3%) 4(6.7%)
Erythromycin 10 52(86.7%) 8(13.3%)
Streptomycin 30 47(78.3%) 13(21.7%)
Rocephin 25 43(71.7%) 17(28.3%)
Septrin 30 43(71.7%) 17(28.3%)
Gentamycin 10 38(63.3%) 22(36.7%)
Zinnacef 20 19(31.7%) 41(68.3%)
Ampiclox 10 11(18.3%) 49(81.7%)
Amoxicillin 30 9(15.0%) 51(85.0%)
Antibiotic Organisms Staphylococcus
aureus
n= 31
Coagulase negative
Staphylococcus spp.
n= 17
Streptococcus spp.
n= 12
TOTAL
n= 60
Ampiclox Sensitivity 5(16.0%) 5(23.0%) 1(8.0%) 11(18.3%)
Resistance 26(84.0%) 12(70.6%) 11(92.0%) 49(81.7%)
Zinnacef Sensitivity 10(32.0%) 6(35.0%) 3(25.0%) 19(31.7%)
Resistance 21(68.0%) 11(65.0%) 9(75.0%) 41(68.3%)
Amoxicillin Sensitivity 5(16.0%) 3(17.6%) 1(8.0%) 9(15.0%)
Resistance 26(84.0%) 14(82.4%) 11(92.0%) 51(85.0%)
Rocephin Sensitivity 26(84.0%) 11(65.0%) 6(50.0%) 43(71.7%)
Resistance 5(16.0%) 6(35.0%) 6(50.0%) 17(28.3%)
Gentamycin Sensitivity 20(64.5%) 14(82.4%) 4(33.3%) 38(63.3%)
Resistance 11(35.5%) 3(17.6%) 8(66.7%) 22(36.7%)
Septrin Sensitivity 23(74.2%) 14(82.4%) 6(50.0%) 43(71.7%)
Resistance 8(25.8%) 3(17.6%) 6(50.0%) 17(28.3%)
Streptomycin Sensitivity 24(77.4%) 17(100.0%) 6(50.0%) 47(78.3%)
Resistance 7(22.6%) 0(0.0%) 6(50.0%) 13(21.7%)
Perfloxacin Sensitivity 29(93.5%) 17(100.0%) 10(83.3%) 56(93.3%)
Resistance 2(6.5%) 0(0.0%) 2(16.7%) 4(6.7%)
Ciprofloxacin Sensitivity 31(100.0%) 17(100.0%) 10(83.3%) 58(96.7%)
Resistance 0(0.0%) 0(0.0%) 2(16.7%) 2(3.3%)
Erythromycin Sensitivity 26(84.0%) 17(100.0%) 9(75.0%) 52(86.7%)
Resistance 5(16.0%) 0(0.0%) 3(25.0%) 8(13.3%)
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Chart 2: Antibiotic resistance patterns for Gram positive isolates
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Table 4: Antibiotic resistance patterns for Gram negative isolates
Antibiotics Organisms Escherichia coli
N= 41
Proteus species
N=38
Klebsiella
species
N=20
Acinetobact
er species
N=20
Pseudomonas
species
N=15
Actinobacter
species
N=15
Citrobacter
species
N=13
Total
N= 162
Amoxacillin Sensitivity 19 (46.3%) 9 (23.7%) 14 (70.0%) 8 (40.0%) 6 (40.0%) 6 (40.0%) 4 (30.8%) 66 (40.7%)
Resistance 22 (53.7%) 29 (76.3%) 6 (30.0%) 12 (60.0%) 9 (60.0%) 9 (60.0%) 9 (69.2%) 96 (59.3%)
Augmentin Sensitivity 21 (51.2% ) 9 (23.7% ) 14 (70.0%) 9 (45.0%) 1 (6.7%) 5 (33.3%) 2 (15.4%) 61 (37.7% )
Resistance 20 (48.8% ) 29 (76.3%) 6 (30.0%) 11 (55%) 14 (93.3%) 10 (66.7%) 11 (84.6%) 101 (62.3% )
Septrin Sensitivity 25 (61.0%) 9 (23.7% ) 13 (65.0%) 10 (50%) 7 (46.7%) 10 (66.7%) 8 (61.5%) 82 (50.6% )
Resistance 16 (39.0%) 29 76.3%) 7 (35.0%) 10 (50%) 8 (53.3%) 5 (33.3%) 5 (38.5%) 80 (49.4% )
Chloramphenicol Sensitivity 32 (78.0%) 18 (47.4% ) 13 (65.0%) 13 (65.0%) 10 (66.7%) 11 (73.3%) 9 (69.2%) 106 (65.4% )
Resistance 9 (22.0% ) 20 (52.6%) 7 (35.0%) 7 (35.0%) 5 (33.3%) 4 (26.7%) 4 (30.8%) 56 (34.6% )
Sparfloxacin Sensitivity 35 (85.4%) 31 (81.6% ) 17 (85.0% ) 16 (80.0% ) 15 (100.0% ) 12 (80.0%) 10 (76.9%) 136 (84.0% )
Resistance 6 (14.6% ) 7 (18.4%) 3 (15.0%) 4 (20.0% ) 0 (0.0% ) 3 (20.0%) 3 (23.1%) 26 (16.0% )
Ciprofloxacin Sensitivity 38 (92.7%) 32 (84.2%) 19 (95.0%) 17 (85.0% ) 15 (100.0%) 14 (93.3%) 12 (92.3%) 147 (90.7%)
Resistance 3 (7.3%) 6 (15.8%) 1 (5.0% ) 3 (15.0% ) 0 (0.0%) 1 (6.7%) 1 (7.7%) 15 (9.3%)
Gentamycin Sensitivity 29 (70.7%) 21 (55.3%) 15 (75.0%) 11 (55.0%) 7 (46.7%) 11 (73.3%) 9 (69.2%) 103 (63.6%)
Resistance 12 (29.3% ) 17 (44.7% ) 5 (25.0% ) 9 (45.0% ) 8 (53.3% ) 4 (26.7%) 4 (30.8%) 59 (36.4% )
Perfloxacin Sensitivity 37 (90.2%) 31 (81.6% ) 15 (75.0%) 16 (80.0% ) 13 (86.7%) 12 (80.0%) 10 (76.9%) 134 (82.7%)
Resistance 4 (9.8%) 7 (18.4%) 5 (25.0% ) 4 (20.0% ) 2 (13.3%) 3 (20.0%) 3 (23.1%) 28 (17.3%)
Ofloxacin Sensitivity 33 (80.5%) 26 (68.4%) 15 (75.0%) 16 (80.0% ) 15 (100.0%) 12 (80.0%) 10 (76.9%) 127 (78.4%)
Resistance 8 (19.5%) 12 (31.6%) 5 (25.0% ) 4 (20.0% ) 0 (0.0%) 3 (20.0%) 3 (23.1%) 35 (21.6%)
Streptomycin Sensitivity 27 (65.9%) 20 (52.6%) 16 (80.0% ) 11 (55%) 9 (60.0%) 10 (66.7%) 8 (61.5%) 101 (62.3%)
Resistance 14 (34.1%) 18 (47.4% ) 4 (20.0% ) 9 (45%) 6 (40.0%) 5 (33.3%) 5 (38.5%) 61 (37.7%)
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Table 5: Antibiotic resistance patterns for Gram negative isolates
Chart 3: Antibiotic resistance patterns for Gram negative isolates
Table 6: Resistance patterns of Gram positive bacteria isolates.
Resistant Pattern Staphylococcus aureus Coagulase Negative
Staphylococcus species
Streptococcus species
AM 1 0 0
APX,AM 1 1 1
APX, AM, Z 6 1 0
APX,AM, CN 0 1 0
APX, AM, Z,R 2 1 0
APX, Z, CN,S 1 0 0
APX,AM, CN,R 0 1 0
APX, AM, Z, CN, 1 0 1
APX, AM, Z,SXT 3 0 0
APX, AM, Z, PEF 0 0 1
APX, AM, Z, CN,R 3 0 0
APX, AM, Z,SXT,E 0 1 0
APX, AM, Z, CN, SXT,S 0 1 0
APX, AM, Z, CN, SXT, S,E 1 0 0
APX, AM, Z, CN,R,SXT,S 0 0 2
APX, AM, Z, CN, R, SXT, S,E 1 0 2
LEGEND: PEF- Perfloxacin, E- Erythromycin, SXT- Streptomycin, S- Septrin, CN- Gentamycin,
Z- Zinnacef, APX- Ampiclox, AM- Amoxacillin
Antibiotics Amount (µg) Sensitive Resistant
Ciprofloxacin 5 147 (90.7%) 15 (9.3%)
Sparfloxacin 10 136 (84.0% ) 26 (16.0% )
Perfloxacin 10 134 (82.7%) 28 (17.3%)
Ofloxacin 5 127 (78.4%) 35 (21.6%)
Chloramphenicol 30 106 (65.4% ) 56 (34.6% )
Gentamycin 10 103 (63.6%) 59 (36.4% )
Streptomycin 10 101 (62.3%) 61 (37.7%)
Septrin 30 82 (50.6% ) 80 (49.4% )
Amoxicillin 30 66 (40.7%) 96 (59.3%)
Augmentin 30 61 (37.7% ) 101 (62.3% )
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Table 7: Resistance patterns of Gram negative bacteria isolates
Resistant pattern E. coli Proteus
species
Klebsiella
species
Acinetobacter
species
Pseudomon
as species
Actinobacter species Citrobacter
species
AU 0 0 1 0 2 2 1
SXT 1 1 0 0 0 0 0
GN 1 0 0 0 0 0 0
CH 0 0 1 0 0 0 1
CPX 0 0 0 0 0 0 1
AM 1 0 0 0 0 0 0
S 0 1 0 1 0 0 0
AU, SXT 0 2 0 0 0 0 0
AU, AM 2 0 0 0 2 1 0
AU, GN 0 0 0 1 0 0 0
SXT, CH 0 0 1 0 0 0 0
SXT, S 1 0 0 0 0 0 0
S, OFX 1 0 0 0 0 0 0
AU, S 0 0 0 0 1 0 0
AU, AM, PEF 0 0 0 0 0 1 0
AU , AM, CH 0 1 0 0 0 1 0
SXT, OFX, S 0 0 0 1 0 0 0
AU, AM, SXT 2 1 0 1 2 0 0
AU, GN, CH 0 1 0 0 0 0 0
AU, AM, S 0 1 0 0 0 0 0
AU, AM, GN 2 0 1 0 0 0 0
AU, SXT, CH, 0 0 2 1 0 0 0
AM, SXT, CH 0 1 0 0 0 0 0
S, AM, GN 0 0 0 1 0 0 0
AU, AM, GN, S 0 0 0 1 1 0 0
AU, AM, CH, SP 1 0 0 0 0 0 0
AU, AM, GN 1 1 0 0 1 0 0
AU, SXT, S, CH 0 0 0 0 0 0 1
AU, AM, GN, OFX 0 0 0 0 0 0 1
AU, AM, SXT, CH 0 1 0 1 0 0 0
AM, SXT, OFX, PEF 0 0 1 0 0 0 0
SXT, GN, CH, OFX 0 1 0 0 0 0 0
AU, AM, SXT, S 1 2 0 0 0 0 0
AU, SXT, GN, CH 0 0 0 1 1 0 0
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LEGEND:
AU- augmentin
(30μg), GN- gentamycin (10μg), CPX- ciprofloxacin (5μg), CH- chloramphenicol (30μg) 
PEF- perfloxacin (10μg), SXT- streptomycin (10μg), AM- amoxicillin (30μg), SP- Sparfloxacin (10μg)
OFX- ofloxacin (5μg), S septrin (30μg) 
AU, AM, SXT, GN,CH 0 1 0 0 1 1 0
AU, AM, SXT, GN, S 1 1 0 0 1 0 0
AU, AM, SXT, S, CH 0 1 0 0 0 1 0
AU, AM, GN, OFX, PEF 0 1 0 0 0 0 1
AU, AM, SXT, S, OFX 1 0 0 0 0 0 0
AU, AM, SXT, CH, SP 0 1 0 0 0 0 0
AU, S, SXT, CH, OFX, 0 1 0 0 0 0 0
AU, AM, SXT, GN, S, 0 0 0 0 1 0 0
AU, AM, SXT, GN, CH 0 1 0 0 0 0 0
AM, SXT, S , CH, CPX 0 1 0 0 0 0 0
AU, AM, SXT, S, SP 1 0 0 0 0 0 1
AU, AM, GN, S, OFX, PEF 0 0 1 0 0 0 0
AU, AM, SXT, S, OFX, SP 0 1 0 0 0 0 0
AU, AM, SXT, GN, S, CH, 2 0 0 0 1 0 0
AU, AM, SXT, GN, S, OFX 0 0 0 0 0 0 1
AU, AM, GN, S, PEF, SP 0 0 0 1 0 0 0
AU, AM, SXT, S, CH, OFX 1 0 0 0 0 0 0
AU, AM, SXT, GN, S, CH 0 0 0 0 0 0 3
AU, AM, SXT, GN, S, OFX 0 0 0 0 0 1 0
AU, AM, SXT, GN, CH, OFX,
PEF
0 1 0 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, PEF
1 0 0 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, PEF
0 0 1 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, CPX
0 0 1 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, SP, CPX
2 0 0 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, PEF, CPX
0 1 0 0 0 0 0
AU, AM, SXT, GN, S, CH,
OFX, PEF, SP
1 0 2 0 0 0 1
AU, AM, SXT, GN, S, CH,
OFX, PEF, SP, CPX
1 4 1 2 1 1 1
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Discussion and Conclusion
A total of 222 bacteria isolates were cultured from the 173 nasal swab samples, out of which 10 potentially pathogenic
bacteria including 3 Gram positive bacteria (Staphylococcus aureus 14.0%, coagulase negative Staphylococcus species 7.7% and
Streptococcus species 5.4%) and 7 Gram negative bacteria (Escherichia coli 18.5%, Proteus species 17.1%, Klebsiella species 9.0%,
Acinetobacter species 9.0%, Pseudomonas species 6.8%, Actinobacter species 6.8% and Citrobacter species 5.9%) were identified.
The most frequently isolated bacteria in decreasing order included Escherichia coli (18.5%), Proteus species (17.1%),
Staphylococcus aureus (14.0%), Klebsiella species (9.0%), Acinetobacter species (9.0%), coagulase negative Staphylococcus species
(7.7%), Pseudomonas species (6.8%), Actinobacter species (6.8%) and Citrobacter species (5.9%) (Table 1). This result is in close
agreement with Bauer et al. 2003 who reported the presence of 17 different bacterial species of Enterobacteriaceae, Staphylococci
species and Streptococci species, from nasal swabs of healthy dog. Most of these bacteria have been implicated in respiratory
disease in dogs and human (Adaszek et al., 2009; Meyer et al., 2010; Lansing et al., 2002; Spaterna et al., 2012). The susceptible
dogs may present varying clinical signs such as coughing, nasal discharge, sneezing, difficulty in breathing, fever, loss of appetite
and lethargic behavior (Ayodhya et al., 2013). In this study, Bacillus species was disregarded because this might have been obtained
from the surrounding soil, though it can also cause respiratory disease (Maden et al., 2000; Amin et al., 2015).
Less than 50% of Gram positive isolates (31.7%) were sensitive to second generation cephalosporin- cefuroxine
(zinnacef). The next drugs include Ampiclox (18.3% for Gram positive and 40.7% for Gram negative isolates), Amoxicillin (15.0%
for Gram positive) and Augmentin (37.7% for Gram negative isolates). Owing to these low sensitivities, the selection of Amoxicillin
and Ampiclox among drugs of choice for first line therapy of dog with pneumonia is weakened (Lesley, 2010) since anyone of these
isolates can cause respiratory disease. The susceptibility level was highest to ciprofloxacin for Gram positive 58 (96.7%) and Gram
negative (90.7%) bacteria (table 3 and 5). Other fluoroquinolones such as Perfloxacin, Sparfloxacin and Ofloxacin had sensitivity
ranging from 78.4% to 93.3% (Tables 3 and 5).
A pathogen is multidrug resistant (MDR) when it is resistant to three or more antibiotics at any given time (Jan et al.,
2004). The antibiotic susceptibility pattern suggested that the isolated bacteria have strains which possessed varying MDR genes.
This finding was also reported by Davis et al., 2014 who reported the presence of multiple antibiotic resistances of Staphylococcus
species isolated from healthy dog and cats. However, Staphylococcus aureus strains were 100% sensitive to Ciprofloxacin while
coagulase negative Staphylococcus species strains were 100% sensitive to Ciprofloxacin, Perfloxacin, Streptomycin and
Erythromycin (Table 2). MDR among normal flora of clinically healthy dogs calls for a great attention since most of them had no
record of antibiotic therapy. The growing antibiotic resistance trend among bacteria in humans and animals in both diseased and
clinically healthy state, instigates a need for continuous research to avert the impending danger of antibiotic resistance (CDC, 2010;
Coates et al., 2002; FDA, 2000).
Interestingly, more than 80 percent of human contacts (82%) have had less than 50 cm face-to-face closeness with these
dogs; thus possessing a great risk of acquiring MDR pathogens. These human contacts have high chance of inhaling aerosolized
bacteria from the body surfaces such as skin, oral cavity, nasal cavity etc. (Henning et al., 2001) especially when those areas are
disturbed by hand rubbing on the fur, excessive exercise etc. If this contaminated air is breathed in by man, within three feet (90 cm),
there is risk of acquiring such pathogen (W.H.O., 2005). The presence of MDR bacteria among healthy dogs suggested that these
dogs (companion animals) are reservoir of multidrug-resistant potentially pathogenic bacteria, which may be transferred to human,
especially the closest human contacts and others who handle them in unabated endangering habit. Such carriage poses an underlying
risk of infection and this should be considered during handling of healthy dogs by all in-contact humans such as dog owners,
veterinary personnel and students etc. Although, the settling of these airborne bacteria from these dogs on the human respiratory
epithelium may not result into infection or disease state, the exchange of antibiotic resistant genes (plasmid) should not be taken
lightly (Lee, 2003). Transfer of antibiotic resistant plasmid in bacteria has been documented (Lansing et al., 2002). These can make
an antibiotic susceptible bacterium to be resistant to same after acquiring resistant plasmid. It is of importance to implement
strategies to reduce the rate of appearance and spread of resistance bacteria to allow new drug discovery to catch up with bacteria
resistance development.
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